NCT04562155[Secondary Source ID] - Search Results

Your saved search

Your RSS Feed

Year	Number of Results
2022	1
2023	1
2025	1

Page 1

Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.

Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L, Niimi A, Gude K, Krahn U, Saarinen R, Pires PV, Wosnitza M, McGarvey L; PAGANINI Investigators. Dicpinigaitis PV, et al. Lung. 2023 Jun;201(3):255-266. doi: 10.1007/s00408-023-00621-x. Epub 2023 Jun 1. Lung. 2023. PMID: 37261531 Free PMC article. Clinical Trial.

Psychometric validation of the severity of chronic cough diary, leicester cough questionnaire, and a cough severity visual analogue scale in patients with refractory chronic cough.

Trigg A, Clarke N, Gerlinger C, Krahn U, Gater A, Haberland C. Trigg A, et al. J Patient Rep Outcomes. 2025 Jun 11;9(1):65. doi: 10.1186/s41687-025-00888-z. J Patient Rep Outcomes. 2025. PMID: 40498172 Free PMC article. Clinical Trial.

Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis.

Fletcher MC. Fletcher MC. Purinergic Signal. 2022 Mar;18(1):1-3. doi: 10.1007/s11302-021-09831-5. Epub 2022 Jan 3. Purinergic Signal. 2022. PMID: 34978027 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year